- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.02. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models | 248 | ACCESS Newswire | Iron-rescue experiments confirm tumor cell mortality is mechanistically driven, not nonspecific cytotoxicity. MIAMI, FL / ACCESS Newswire / February 17, 2026 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)... ► Artikel lesen | |
| 17.02. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 05.02. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging | 682 | ACCESS Newswire | Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic... ► Artikel lesen | |
| 05.02. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 13.01. | Rodman & Renshaw initiates Telomir Pharma stock with Buy rating | 1 | Investing.com | ||
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 05.01. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models | 292 | ACCESS Newswire | In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS Newswire... ► Artikel lesen | |
| 05.01. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.12.25 | Telomir Pharmaceuticals beschließt neues Vergütungspaket für CEO | 3 | Investing.com Deutsch | ||
| 18.12.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development | 321 | ACCESS Newswire | No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir... ► Artikel lesen | |
| 17.12.25 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.11.25 | RECIPHARM AB: Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support | 2 | Cision News | ||
| 25.11.25 | Telomir reports PSA reduction in prostate cancer cells with lead drug | 2 | Investing.com | ||
| 25.11.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells | 292 | ACCESS Newswire | PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November... ► Artikel lesen | |
| 21.11.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells | 377 | ACCESS Newswire | Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL... ► Artikel lesen | |
| 20.11.25 | Craig Eagle verlässt Aufsichtsrat von Telomir Pharmaceuticals | 1 | Investing.com Deutsch | ||
| 20.11.25 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine in Reducing Intracellular Iron in a Human Cell Line | 370 | ACCESS Newswire | New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating... ► Artikel lesen | |
| 12.11.25 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.11.25 | Telomir Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 23.10.25 | Telomir-1 shows promise in modulating cancer defense genes | 13 | Investing.com |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,60 | +0,32 % | BioNTech SE: BioNTech veröffentlicht am 10. März 2026 Ergebnisse für das vierte Quartal und das Geschäftsjahr 2025 und informiert über operativen Fortschritt | MAINZ, Deutschland, 24. Februar 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Dienstag, den 10. März 2026, die Ergebnisse für das vierte Quartal und... ► Artikel lesen | |
| MODERNA | 46,325 | +2,16 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| VALNEVA | 4,746 | +0,34 % | BioNTech, Valneva oder BB Biotech: Warum es HIER in Kürze knallt! | Die Biotechbranche steht zu Beginn des Jahres 2026 erneut im Spannungsfeld zwischen wissenschaftlicher Innovation und wachsender Skepsis der Kapitalmärkte. Nach Jahren extremer Kursbewegungen prüfen... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,500 | -2,60 % | Is Inovio Pharmaceuticals Stock Going to $0? | ||
| OCUGEN | 1,620 | +5,47 % | Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa | Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,920 | +0,84 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| BAVARIAN NORDIC | 25,590 | -2,77 % | Bavarian Nordic A/S: Paul Chaplin Steps Down as CEO of Bavarian Nordic | COPENHAGEN, Denmark, March 2, 2026 - Bavarian Nordic A/S (OMX: BAVA) announced today, that the Board of Directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal... ► Artikel lesen | |
| GERON | 1,363 | -3,91 % | Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Achieved $48 million and $184 million in RYTELO (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within... ► Artikel lesen | |
| IMMUNITYBIO | 9,026 | +8,88 % | ImmunityBio, Inc.: ImmunityBio Reports 700% Year-Over-Year Revenue Growth, Expanded ANKTIVA Approvals in Lung Cancer and Global Commercial Partnerships in 33 Countries with Label Expansion Plans Globally | 2025 Sales Momentum: ANKTIVA net product revenue increased 20% quarter-over-quarter, with full-year net product revenue of $113 million, representing an approximately 700% increase year-over-year... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,232 | -1,72 % | Iovance Biotherapeutics, Inc.: Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas | 50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE... ► Artikel lesen | |
| ZAI LAB LTD ADR | 15,500 | -4,32 % | Zai Lab outlines 2026 transition year with multiple late-stage catalysts and targets first global approval by 2028 | ||
| VERASTEM | 4,900 | +1,24 % | Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma | GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 17,390 | -1,87 % | Apellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Full-year 2025 net product revenues of $689 million SYFOVRE- (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI- (pegcetacoplan) full year 2025 net product revenue... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,680 | +7,06 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| ANNOVIS BIO | 2,225 | -2,20 % | Annovis Bio Inc.: Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease | MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy... ► Artikel lesen |
TELOMIR PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,005 (-0,40 %) liegt der Kurs bei 1,245 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.